Literature DB >> 33626006

Diagnosis of liver fibrosis in patients with hepatitis B-related liver disease using ultrasound with wave-number domain attenuation coefficient.

Danqing He1, Chaoxue Zhang1, Wenqian Qiu1, Qinxiu Xie2.   

Abstract

BACKGROUND/AIMS: The importance of identifying the stage of liver fibrosis has motivated the development of non-invasive methods. This study aimed to evaluate the applicability of ultrasound analysis involving the wave-number domain attenuation coefficient (W-Ac) in the non-invasive quantitative differentiation of liver fibrosis.
MATERIALS AND METHODS: This was a prospective study of inpatients with hepatitis B-related liver disease treated between October 2016 and January 2018. In ultrasound, the echo from the near-field liver tissue was selected as the reference signal. The W-Ac of liver tissues was based on the fast Fourier transform of the acquired post-beamforming radio frequency signals. These values were compared with fibrosis from biopsy METAVIR score results. A receiver operating characteristic (ROC) curve tested the W-Ac method.
RESULTS: A total of 46 patients were enrolled, including 27 males and 19 females. Fibrosis was stage F0 in 12 patients, F1 in 13 patients, F2 in 10 patients, F3 in 7 patients, and F4 in 4 patients. W-Ac increased with the progression of liver fibrosis up to stage F3. There were differences between F0 and F4 stages (p<0.001) and between any 2 stages of fibrosis (p<0.05), except for stages F3 and F4. There was a significant correlation between W-Ac and METAVIR score (r=0.795, p<0.001). W-Ac differed between non-fibrosis (F0) and fibrosis (F1-F4) groups (p<0.001) and in the normal (F0), early fibrosis (F1-2), and late fibrosis groups (F3-4) (p<0.001). ROC area under the curve was 0.890, and at a cut-off of 0.12153, sensitivity was 0.706 and specificity was 0.830.
CONCLUSIONS: W-Ac allowed assessment of liver fibrosis in clinical practice.

Entities:  

Year:  2020        PMID: 33626006      PMCID: PMC7928246          DOI: 10.5152/tjg.2020.20139

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  32 in total

Review 1.  Non-invasive diagnosis of liver fibrosis and cirrhosis.

Authors:  Yoav Lurie; Muriel Webb; Ruth Cytter-Kuint; Shimon Shteingart; Gerardo Z Lederkremer
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

2.  Non-invasive assessment of liver fibrosis using acoustic structure quantification: comparison with transient elastography in chronic viral hepatitis.

Authors:  Tae-Hoon Nam; Beom Jin Park; Deuk Jae Sung; Min Ju Kim; Na Yeon Han; Ki Choon Sim; Jean H Lee; Sung Bum Cho
Journal:  Abdom Radiol (NY)       Date:  2016-02

3.  Characterization of in vitro healthy and pathological human liver tissue periodicity using backscattered ultrasound signals.

Authors:  Christiano Bittencourt Machado; Wagner Coelho de Albuquerque Pereira; Mahmoud Meziri; Pascal Laugier
Journal:  Ultrasound Med Biol       Date:  2006-05       Impact factor: 2.998

4.  Assessment of serum Golgi protein 73 as a biomarker for the diagnosis of significant fibrosis in patients with chronic HBV infection.

Authors:  Z Cao; Z Li; Y Wang; Y Liu; R Mo; P Ren; L Chen; J Lu; H Li; Y Zhuang; Y Liu; X Wang; G Zhao; W Tang; X Xiang; H Wang; W Cai; L Liu; C Zhu; S Bao; Q Xie
Journal:  J Viral Hepat       Date:  2017-11       Impact factor: 3.728

5.  Doppler ultrasonography combined with transient elastography improves the non-invasive assessment of fibrosis in patients with chronic liver diseases.

Authors:  Tamara Alempijevic; Simon Zec; Vladimir Nikolic; Aleksandar Veljkovic; Zoran Stojanovic; Vera Matovic; Tomica Milosavljevic
Journal:  Med Ultrason       Date:  2017-01-31       Impact factor: 1.611

6.  Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease.

Authors:  Raj Vuppalanchi; Mohammad S Siddiqui; Mark L Van Natta; Erin Hallinan; Danielle Brandman; Kris Kowdley; Brent A Neuschwander-Tetri; Rohit Loomba; Srinivas Dasarathy; Manal Abdelmalek; Edward Doo; James A Tonascia; David E Kleiner; Arun J Sanyal; Naga Chalasani
Journal:  Hepatology       Date:  2017-11-29       Impact factor: 17.425

7.  Regression of fibrosis/cirrhosis by Glycine propionyl-l-carnitine treatment in d-Galactosamine induced chronic liver damage.

Authors:  Ajaz Ahmad Ganai; Ishfaq Ahmad Ganaie; Nishika Verma; Humaira Farooqi
Journal:  Chem Biol Interact       Date:  2016-11-09       Impact factor: 5.192

Review 8.  Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis.

Authors:  Eva Herrmann; Victor de Lédinghen; Christophe Cassinotto; Winnie C-W Chu; Vivian Y-F Leung; Giovanna Ferraioli; Carlo Filice; Laurent Castera; Valérie Vilgrain; Maxime Ronot; Jérôme Dumortier; Aymeric Guibal; Stanislas Pol; Jonel Trebicka; Christian Jansen; Christian Strassburg; Rongqin Zheng; Jian Zheng; Sven Francque; Thomas Vanwolleghem; Luisa Vonghia; Emanuel K Manesis; Pavlos Zoumpoulis; Ioan Sporea; Maja Thiele; Aleksander Krag; Claude Cohen-Bacrie; Aline Criton; Joel Gay; Thomas Deffieux; Mireen Friedrich-Rust
Journal:  Hepatology       Date:  2017-11-15       Impact factor: 17.425

9.  Serum MicroRNA Levels as a Noninvasive Diagnostic Biomarker for the Early Diagnosis of Hepatitis B Virus-Related Liver Fibrosis.

Authors:  Suxia Bao; Jianming Zheng; Ning Li; Chong Huang; Mingquan Chen; Qi Cheng; Kangkang Yu; Shengshen Chen; Mengqi Zhu; Guangfeng Shi
Journal:  Gut Liver       Date:  2017-11-15       Impact factor: 4.519

10.  Accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C.

Authors:  Taisa Grotta Ragazzo; Denise Paranagua-Vezozzo; Fabiana Roberto Lima; Daniel Ferraz de Campos Mazo; Mário Guimarães Pessoa; Claudia Pinto Oliveira; Venancio Avancini Ferreira Alves; Flair José Carrilho
Journal:  Clinics (Sao Paulo)       Date:  2017-10       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.